Fertility
Klinikk Hausken deploys Fairtility’s CHLOE technology, bringing transparent AI solution to Norway’s largest fertility network
Klinikk Hausken validated CHLOE technology on large data sets in two of its embryology labs prior to implementation
Fairtility, the transparent AI innovator powering reproductive care for improved outcomes, has announced that Klinikk Hausken, part of Medicover and Norway’s largest fertility network, has successfully deployed Fairtility’s CHLOE technology in all five of its embryology labs.
“We selected CHLOE EQ™ for its unmatched ability to provide quantifiable biological data on embryo development in language that our embryologists trust: human biology,” said said Shabana Sayed, senior embryologist and IVF lab manager at Klinikk Hausken, part of Medicover.
“Its transparency and interpretability set it apart from other AI-based decision support tools available.
“CHLOE EQ’s reliability and transparency have been instrumental in both our clinical and embryology teams wholeheartedly embracing AI technology in our routine workflow.
“Offering this transparency to both our internal teams and our patients is transformative to the IVF journey, which has historically been a ‘black box’ process.”
Klinikk Hausken validated CHLOE technology on large data sets in two of its embryology labs prior to implementation. Following this process, Norway’s largest fertility network implemented CHLOE technology into workflows across its clinics.
Despite utilising different time lapse incubator (TLI) systems in its various labs, CHLOE integration was seamless across TLIs and with the network’s electronic medical record system.
“CHLOE technology is bringing standardisation to the subjective and differentiated decision-making that takes place in embryology labs, where protocols and equipment may differ from lab to lab, and with embryologists having varying levels of experience,” explained Eran Eshed, co-founder and CEO of Fairtility.
“CHLOE EQ augments embryologists’ abilities and reduces their administrative time, essentially super-charging each embryologist to be more effective in the lab while reducing risk-factors for burnout.”
CHLOE EQ has augmented and standardised decision-making processes for selecting the most viable embryos for transfer or for cryopreservation.
It provides automated annotations of embryos’ biological development, including morphokinetic timings and provides accurate predictions for blastocyst development and expansion.
Supporting clinical decision-making and streamlining workflows has also resulted in operational benefits. Klinikk Hausken can now more efficiently schedule embryo transfers for patients at the optimal point in embryos’ development process.
Additionally, CHLOE EQ reports are utilised in daily treatment summary meetings with clinical and nursing staff, ensuring patients receive consistent, reliable and accurate information about their embryo quality.
Klinikk Hausken is Norway’s largest private IVF network, supporting over 1,500 IVF cycles annually. The network is committed to investing in its team and its technology, all to support improved patient care, as prospective parents pursue their dreams of having children.

Entrepreneur
Kindbody unveils next-gen fertility platform
Fertility
Baby2Home app boosts new mothers’ mental health
First-time mothers using the Baby2Home app for a year after birth reported fewer symptoms of stress, depression and anxiety than those receiving usual postpartum care.
The study found women randomised to the app reported better overall health than first-time mothers who received usual care alone.
Baby2Home is a digital tool to help new families with newborn care and staying healthy.
It offers tailored educational content, infant care trackers and mental health self-management tools, plus access to a care manager for on-demand mental health and problem-solving support.
Emily S. Miller is principal investigator and division director of maternal-fetal medicine at Women & Infants Hospital of Rhode Island.
She said: “Evidence-based digital tools like Baby2Home are opening the door to a new era of postpartum care.
“We can now extend high-quality support beyond hospital walls and into families’ everyday lives. The mental health improvements we saw underscore just how transformational that support can be.”
Researchers from Women & Infants Hospital of Rhode Island, Warren Alpert Medical School of Brown University, Northwestern University’s Feinberg School of Medicine and Lurie Children’s Hospital of Chicago ran a multi-site randomised controlled trial between November 2022 and July 2025.
The trial enrolled 642 postpartum patients, all first-time parents. For 12 months after birth, all participants received usual postpartum care; half also used the Baby2Home smartphone app.
Participants reported progress electronically at five time points over the first year. Compared with the control group, those assigned to Baby2Home reported significantly fewer symptoms of stress, depression and anxiety.
They also reported better overall health, higher relationship satisfaction with partners and family members, and greater confidence in their parenting than the control group.
Miller said: “The first year after birth is a critical period for parental mental health. Baby2Home helped new parents feel more confident, more supported and more connected.
“That translated into better health outcomes for them and their families.”
Wellness
Most NHS regions in England limit IVF to single cycle, research finds
Nearly 70 per cent of NHS regions in England fund only one IVF cycle for women under 40, breaking national guidelines, new research has found.
Twenty-nine of the 42 integrated care boards, which control local NHS budgets, now offer only one round of treatment, after four reduced access in the past year.
National Institute for Health and Care Excellence (Nice) guidelines recommend three full cycles for women under 40 who have been unable to conceive for two years.
Only two of England’s 42 integrated care boards have policies consistent with these guidelines, which they are not legally obliged to follow.
The research was conducted by the Progress Educational Trust, a fertility charity.
Sarah Norcross, the director of PET, said the impact was “devastating” for couples struggling with infertility.
She said: “Infertility is already incredibly stressful for people, and it puts them under even more pressure, because there is so much riding on whether that one NHS-funded cycle is going to work.
“And for some people, that will be their only chance, because private fertility treatment is so expensive.”
The data showed regional variations, with the whole of the north-west offering just one cycle.
“It’s a postcode lottery, and we’re seeing a race to the bottom,” said Norcross.
Of the 29 integrated care boards that offer a single cycle, 19 provide only a partial cycle, where not all viable embryos created are transferred.
There was just one recent example of improved services, from NHS South East London, which in July 2024 went from one partial to two full cycles.
The NHS estimates that about one in seven couples may have difficulty achieving a pregnancy. One cycle of IVF can cost from £5,000 at a private clinic.
Fertility rates in England and Wales have fallen since 2010 to 1.41 children per woman in 2024, the lowest on record and below the replacement level of 2.1 at which a population is stable without immigration.
Health minister Karin Smyth said in a written parliamentary answer last month that it was “unacceptable” that access to NHS-funded fertility services varied across the country.
Revised Nice fertility guidelines are due this spring, but Norcross said changing them seemed pointless.
She said: “Fertility treatment has always been a Cinderella service. It’s always been the one they’ve chosen to cut or to ignore.
“Nice has recommended three full NHS-funded cycles, for women under 40, for more than 20 years. This has never been implemented across England, unlike in Scotland.”
Norcross advocated centralised commissioning and replicating Scotland’s approach, which included financial modelling and a phased implementation starting with two cycles to avoid long waits, moving up to three once capacity was achieved.
“It is a tried and tested plan that England could follow,” Norcross added.
A Department of Health and Social Care spokesperson said: “We recognise access to fertility treatment varies across the country and we are working with the NHS to improve consistency.
“Nice provides clear clinical guidelines, and we expect integrated care boards to commission treatment in line with these.
“Updated Nice fertility guidelines are expected this spring and we will continue to support NHS England to make sure the guidance is fully considered in local commissioning decisions.”
An NHS England spokesperson said: “These clinical services are commissioned by integrated care boards for their area based on the needs of the local population and prioritisation of resources available.
“All ICBs have a responsibility to ensure services are provided fairly and are accessible by different population groups.”
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Menopause3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur6 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Wellness4 weeks agoVerdane invest in Clue to accelerate the future of women’s health






